TY - JOUR
T1 - Economic effects of healthy ageing
T2 - functional limitation, forgone wages, and medical and long-term care costs
AU - Okamoto, Shohei
AU - Sakamoto, Haruka
AU - Kamimura, Kazuki
AU - Komamura, Kohei
AU - Kobayashi, Erika
AU - Liang, Jersey
N1 - © 2023. The Author(s).
PY - 2023/5/10
Y1 - 2023/5/10
N2 - This study aims to estimate the potential economic benefits of healthy ageing by obtaining estimates of the economic losses generated by functional limitations among middle-aged and older people. Utilising two data sources retrieved from nationally representative samples of the Japanese people, we analysed the association between functional limitation and economic indicators, including labour market outcomes, savings, investment, consumption, and unpaid activities among individuals aged ≥ 60. Using the estimated parameters from our micro-econometric analyses and the official statistics by the Japanese government and a previous study, we calculated the financial costs that can be averted if healthy ageing is achieved as foregone wages and formal medical/long-term care costs incurred by functional limitations. Our micro-econometric analyses found that functional limitation was associated with a 3% point increase in retirement probability, with a stronger association among those aged 60–69. Moreover, functional limitation was linked with higher total health spending and less active involvement in domestic work. Foregone wages generated by functional limitation were estimated to be approximately USD 266.4 million, driven mainly by individuals in their 60s. Long-term care costs, rather than medical care costs, for older people aged ≥ 85 accounted for most of the additional costs, indicating that the estimated medical and long-term costs generated by functional limitations were approximately USD 72.7 billion. Health interventions can yield economic benefits by preventing exits from the labour market due to health issues and reducing medical and long-term care costs.
AB - This study aims to estimate the potential economic benefits of healthy ageing by obtaining estimates of the economic losses generated by functional limitations among middle-aged and older people. Utilising two data sources retrieved from nationally representative samples of the Japanese people, we analysed the association between functional limitation and economic indicators, including labour market outcomes, savings, investment, consumption, and unpaid activities among individuals aged ≥ 60. Using the estimated parameters from our micro-econometric analyses and the official statistics by the Japanese government and a previous study, we calculated the financial costs that can be averted if healthy ageing is achieved as foregone wages and formal medical/long-term care costs incurred by functional limitations. Our micro-econometric analyses found that functional limitation was associated with a 3% point increase in retirement probability, with a stronger association among those aged 60–69. Moreover, functional limitation was linked with higher total health spending and less active involvement in domestic work. Foregone wages generated by functional limitation were estimated to be approximately USD 266.4 million, driven mainly by individuals in their 60s. Long-term care costs, rather than medical care costs, for older people aged ≥ 85 accounted for most of the additional costs, indicating that the estimated medical and long-term costs generated by functional limitations were approximately USD 72.7 billion. Health interventions can yield economic benefits by preventing exits from the labour market due to health issues and reducing medical and long-term care costs.
KW - D1
KW - Disability
KW - Economic benefits
KW - Functional health status
KW - I1
KW - J14
KW - J26
KW - Long-term care costs
KW - Medical care costs
KW - Retirement
KW - Successful ageing
UR - http://www.scopus.com/inward/record.url?scp=85159085983&partnerID=8YFLogxK
U2 - 10.1186/s13561-023-00442-x
DO - 10.1186/s13561-023-00442-x
M3 - 文章
C2 - 37162614
AN - SCOPUS:85159085983
SN - 2191-1991
VL - 13
SP - 28
JO - Health Economics Review
JF - Health Economics Review
IS - 1
M1 - 28
ER -